Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive to talk through significant progress in the journey of RECCE® 327 (R327) for treating urinary tract infections (UTI) and urosepsis. The company has completed dosing in its Phase 1/2 clinical trial, which focused on evaluating R327's safety and pharmacokinetics at fast infusion rates.
Following the completion of this phase of the trial, an independent safety committee will assess the data. This analysis is crucial for advancing to the next phase of research.
Recruitment has already started for the subsequent cohort, aiming to further investigate R327's effects and prepare for an efficacy trial. The ongoing studies are stepping stones towards potentially establishing R327 as a frontline treatment for UTI and urosepsis. Recce is now not far from transitioning into an efficacy trial.